Please login to the form below

Not currently logged in
Email:
Password:

Pfizer's Inlyta backed by EMA for kidney cancer in EU

Agency recommends drug as second-line therapy in adults with advanced renal cell carcinoma

Pfizer has been granted a positive opinion from the European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP) for its oral protein kinase inhibitor axitinib as a second-line treatment for adults with advanced renal cell carcinoma (RCC).

The positive opinion is for use of Inlyta (axitinib) after failure of earlier treatment with Pfizer's Sutent (sunitinib) or cytokine-based therapy.

In January, the US FDA approved axitinib under the Inlyta brand name as a second-line treatment for advanced RCC, becoming the third Pfizer drug to be registered for the indication after Sutent and Torisel (temsirolimus).

"The benefits with Inlyta are its ability to delay the progression of disease in patients previously treated with sunitinib and its ability to improve the survival and to delay the progression of disease in patients previously treated with cytokines," said the CHMP.

The most common side effects associated with axitinib are diarrhoea, hypertension, fatigue, dysphonia, nausea, decreased appetite, and hand-foot syndrome, it added.

RCC is becoming an increasingly well-served indication, with Bayer/Onyx's Nexavar (sorafenib), GlaxoSmithKline's Votrient (pazopanib), Novartis' Afinitor (everolimus) and Roche/Genentech's Avastin (bevacizumab) all approved to treat various stages of the disease.

Despite the number of treatment options already available, Inlyta is expected to do reasonably well in the marketplace, thanks to data from the phase III AXIS trial. This showed that Inlyta extended progression-free survival (PFS) by 6.7 months compared with Nexavar which extended PFS by 4.7 months.

Analysts have predicted that it will achieve peak sales in excess of $500m a year, perhaps higher if clinical trials expand its use into other indications, such as liver cancer, and first-line therapy in RCC.

Dr Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's oncology division, said: "[D]espite recent advances in the treatment of advanced kidney cancer, there is a clear need for additional treatment options for patients whose disease has progressed following first-line medications."

28th May 2012

Share



Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hall & Partners

We are a specialist brand and communications research consultancy offering you fresh ideas at every stage of the brand planning...

Latest intelligence

Online Physician Communities
Study highlights value of internet for doctors in Eastern Europe
Electronic direct mail is proving popular as online access increases...
England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....